Dear Shareholders,
It's a great pleasure to welcome you all in this 65th Annual
General Meeting of Anuh Pharma Ltd.
Anuh Pharma Ltd founded in 1960 began production of Active
Pharmaceuticals in 1989 at Boisar Maharashtra, specializing in manufacturing of metallic
stearates and antibiotics, with a 150-ton production capacity. Currently, Anuh Pharma Ltd
with capacity of 2400 tons ranks among the world's biggest producers of first-generation
erythromycin salts exporting to over 85 countries and serving 1,200+ customers. Our
stronghold also includes corticosteroids, anti-TB, anti-malarial, and anti-diabetic APIs,
backed by approvals from USFDA, EU-GMP, and WHO Geneva PQ.
The global API industry continues to face pressure from surplus
capacities, price erosion, and rising geopolitical uncertainties. Trade tensions,
including potential tariff reinstatements in the U.S., have added to volatility. Despite
this, India and China remain dominant API players, benefiting from the global shift toward
cost-efficient outsourcing. At Anuh Pharma, we are well-positioned to leverage this trend
through strategic CDMO focus and global market expansion.
Despite the challenging global economic landscape, we have remained
resilient, adaptable, and focused on our strategic objectives. This steadfast dedication
has enabled us to navigate through uncertainties and emerge even stronger.
For the financial year 2024 25, Anuh Pharma Ltd. delivered a stable
performance, effectively navigating the persistent headwinds impacting the global Active
Pharmaceutical Ingredient (API) industry. The company reported total revenue of 670.97
crore,. EBITDA stood at 70.36 crore, with an operating margin of 24.51 % and a net
margin(PAT) of 7.20 %. These results underscore our strong operational discipline and
continued ability to sustain profitability amid pricing pressures and fluctuations in raw
material costs.
Earnings per share (EPS) was 9.45 , while Return on Capital Employed
(ROCE) stood at 18.79 %, reflecting efficient capital allocation and strong returns on
invested resources.
A significant milestone to remember this year was listing on the
National Stock Exchange. This step not only enhanced our corporate visibility and investor
confidence, but also laid a stronger foundation to accelerate our strategic growth
initiatives.
The company's growth strategy is anchored on five key levers:
market penetration, new product launches, geographical expansion, regulatory filings and
inorganic growth. In FY25, Anuh Pharma made strong progress on these fronts launching six
new products, adding 40 new export customers and partnerships, and further strengthening
its regulatory foundation. We now hold 8 CEPs, 5 WHO Prequalification's, and have 3
additional products currently under assessment for both CEP and WHO PQ approvals. These
initiatives reinforce our commitment to expanding global reach and building a
future-ready, compliant product portfolio.
Since the inauguration of a new manufacturing block in 2019, Anuh
Pharma has steadily expanded its infrastructure. What began with 2 API blocks and 1
intermediate block has now grown into a facility housing 3 API blocks and 2 intermediate
blocks. With this expansion, the company now operates a total of 9 API blocks and 2
intermediate blocks, bringing the total installed capacity to 2,400 metric tons per annum.
The company has been actively investing in community development
initiatives such as education, healthcare, sanitation, vocational training, and natural
conservation, reflecting its core commitment to social wellbeing.
Company has adopted water conservation and energy-efficiency measures,
alongside tree-plantation programs and a 3.3 MW solar power project, reinforcing its
commitment to environmental resilience.
As we forge ahead, we recognize that the business landscape is evolving
rapidly. Technological advancements, shifting consumer preferences, and geopolitical
changes present both challenges and opportunities. However, we are confident that with our
robust business model, resilient infrastructure, and dedicated team, we are well-prepared
to navigate the future successfully. We aim to launch 5 6 new APIs in FY26, building on
the momentum of six new products introduced last year to widen our product range. While we
already have a presence in the US, Europe, CIS, and LATAM, our focus will be on growing
the customer base and strengthening relationships in these markets. Further, we are
targeting a 15 16% CAGR in revenue, supported by new products, deeper market reach, and
stronger customer engagement. We shall continue to work on regulatory filings, adding new
customers, and building our presence in key therapeutic areas.
Our unwavering commitment to innovation, customer satisfaction, and
shareholder value will remain at the forefront of our strategic priorities.
We firmly believe that our success is intrinsically linked to the
success of all our stakeholders. We remain deeply committed to creating shared value and
fostering long-term relationships with our valued customers, dedicated employees,
supportive communities, and our esteemed shareholders. Anuh Pharma will continue to
prioritize the interests of all stakeholders, seeking to exceed expectations and
contribute positively to society. We would sincerely like to thank all my fellow directors
for their valued inputs throughout the year, to all stakeholders, including our employees,
customers, shareholders, and partners, for their continued trust and support.
I would also like to thank our bankers HDFC Bank, for their financial
guidance. our Statutory Auditors Jayantilal Thakkar & Co, Internal Auditors SBU &
Co LLP, Secretarial Auditors Pramod Shah & Associates and Ankit Kishor Chande cost
auditor for their diligent contributions during the year.
Their collective efforts have played a key role in enabling Anuh Pharma
Ltd. to maintain strong governance and operational resilience.
Best wishes and warmest regards to all of you and your families.
Thank you
Arun Todarwal
Chairman